SCHEMBL5137288

SCHEMBL5137288

CCCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCCC)Cc1ccc(OC)c(C)c1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
TP53 P04637 1/20 0.43
GAA P10253 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KDM4E B2RXH2 6/20 0.38
ALDH1A1 P00352 6/20 0.38
HPGD P15428 6/20 0.38
HSD17B10 Q99714 6/20 0.38
CYP3A4 P08684 5/20 0.38
TSHR P16473 4/20 0.38
HRH3 Q9Y5N1 2/20 0.38
PDE4B Q07343 2/20 0.38
CRHR1 P34998 2/20 0.38
DRD2 P14416 1/20 0.37
DRD3 P35462 1/20 0.37
BCHE P06276 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648191 0.97 C5AR1 (0.46) C5AR1TP53GAASMN1; SMN2KDM4E
SCHEMBL5137551 0.95 C5AR1 (0.42) C5AR1TP53GAASMN1; SMN2KDM4E
SCHEMBL5070097 0.94 TP53 (0.48) C5AR1TP53GAASMN1; SMN2KDM4E
SCHEMBL5137661 0.93 C5AR1 (0.43) C5AR1TP53GAASMN1; SMN2KDM4E
SCHEMBL5070008 0.93 C5AR1 (0.41) C5AR1TP53GAASMN1; SMN2ALDH1A1
SCHEMBL5135690 0.92 C5AR1 (0.42) C5AR1TP53GAASMN1; SMN2KDM4E
SCHEMBL649655 0.91 C5AR1 (0.47) C5AR1TP53GAASMN1; SMN2ALDH1A1
SCHEMBL651011 0.91 C5AR1 (0.47) C5AR1TP53GAASMN1; SMN2KDM4E
SCHEMBL5135188 0.89 MEN1 (0.42) C5AR1TP53GAASMN1; SMN2KDM4E
SCHEMBL649485 0.88 C5AR1 (0.45) C5AR1TP53GAASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed